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Introduction {#sec1}
============

Bone morphogenetic proteins (BMPs) are critical for normal intestinal homeostasis, counteracting Wnt signaling toward the top of crypts, and allowing differentiation ([@bib15]). BMP antagonists, notably *GREM1*, are expressed in the mesenchyme at the crypt base, restricting BMP activity, potentiating Wnt signaling, and maintaining the epithelial stem cell compartment. Germline mutations in BMP pathway members occur in juvenile polyposis and hereditary mixed polyposis (HMPS) ([@bib8; @bib10]). HMPS is a rare, autosomal-dominant condition in which patients develop multiple types of colorectal polyp and cancer. HMPS results from a 40 kb duplication upstream of *GREM1,* which causes dramatically increased, ectopic *GREM1* expression in the normal epithelium ([@bib11]). In the general population, moreover, single-nucleotide polymorphisms (SNPs) near BMP pathway genes have been found by genome-wide association studies to predispose to colorectal cancer (CRC) ([@bib11; @bib17]).

rs4779584, near *GREM1*, was one of the first CRC SNPs to be found. Interestingly, rs4779584 does not show an association with predisposition to benign colorectal tumors ([@bib3]), suggesting that it may act after tumor initiation. To uncover functional variation tagged by rs4779584, we had previously refined its association signal using direct genotyping, imputation, and conditional logistic regression ([@bib17]). This analysis suggested that rs4779584 captured two independent association signals represented by SNPs rs16969681 and rs11632715 upstream of *GREM1*. In this study, we aimed to identify the functional variation tagged by rs16969681 and characterize the mechanism whereby it influenced CRC risk.

Results and Discussion {#sec2}
======================

rs16969681 Lies in a Region with Features of an Enhancer Element {#sec2.1}
----------------------------------------------------------------

An updated genetic fine-mapping analysis of SNPs upstream of *GREM1* using current SNP reference panels confirmed the existence of two independent CRC risk SNPs (details not shown). One of the signals was still represented by rs16969681. Other SNPs in strong linkage disequilibrium (LD) with rs16969681 showed an ∼20-fold lower likelihood of association with disease ([Table S1](#app2){ref-type="sec"}). Because rs16969681 tags SNPs in intergenic DNA, its association is most likely caused by modifying a gene regulatory element. We therefore investigated the epigenetic characteristics of the rs16969681 region ([Figure 1](#fig1){ref-type="fig"}). ENCODE shows an area of DNase hypersensitivity and transcription factor binding close to rs16969681. However, the cell lines used in these studies are not of intestinal origin, so we wished to expand these studies in appropriate cell types. Although *GREM1* is principally expressed by mesenchymal cells in normal intestine, we found *GREM1* mRNA in 11/32 CRC cell lines (CRCCLs), which are all of epithelial origin ([Figure S1](#app2){ref-type="sec"}). We therefore performed formaldehyde-assisted identification of regulatory elements (FAIRE) in four CRCCLs to identify areas of nucleosome-depleted chromatin in the 25 kb region upstream of the *GREM1* promoter, including rs4779584 and rs16969681. The highest signal in *GREM1*-expressing lines was a 1.3 kb peak centered on rs16969681 ([Figure 1](#fig1){ref-type="fig"}B). Chromatin immunoprecipitation (ChIP) using antibodies against H3K4Me2 (marker of promoters and enhancers) and panH4Ac (marker of active chromatin) also showed signals at rs16969681 and the *GREM1* transcription start site (TSS), specifically in *GREM1-*expressing lines ([Figures 1](#fig1){ref-type="fig"}C and 1D). The chromatin signature was indicative of a regulatory element, probably an enhancer, located at or near rs16969681. In support of this, we demonstrated an interaction between the region containing rs16969681 and *GREM1*'s promoter using chromosome conformation capture ([@bib11]; [Figure S2](#app2){ref-type="sec"}).

The rs16969681 Enhancer Regulates Gene Expression in an Allele-Specific Manner {#sec2.2}
------------------------------------------------------------------------------

We next determined whether the rs16969681 genotype influenced *GREM1* mRNA. rs16969344, a SNP in perfect LD with rs16969681, was not associated with total *GREM1* mRNA levels in The Cancer Genome Atlas CRC samples. However, differences in gene-expression levels among cancers may have many different causes, and we therefore searched for allele-specific expression (ASE) differences. One CRCCL in our panel (COLO320) was heterozygous at rs16969681, had two copies of chromosome 15q, expressed *GREM1*, and was heterozygous for a suitable SNP in the *GREM1* transcript (rs7162202 in the 3′ UTR). We found that the normalized allelic ratio (G:T) of rs7162202 in COLO320 cDNA was 1.62 (p = 0.001; [Figure 2](#fig2){ref-type="fig"}A) compared with 1.1 (p = 0.11) in a control CRCCL homozygous for rs16969681 (SW403), consistent with ASE in COLO320. Due to the large distance (\>30 kb) between rs16969681 and rs7162202 and no suitable cell line for copy-number-based phasing, we could not determine whether the high-risk allele was associated with higher expression in *cis*. We therefore carried out luciferase reporter assays to investigate allele-specific enhancer activity of the rs16969681 region in vitro in SW948 cells ([Figure 2](#fig2){ref-type="fig"}B). Constructs containing the low-risk allele showed moderate enhancing activity, but this was significantly increased when rs16969681 was mutated to the high-risk allele (p \< 0.001). A series of deletion constructs around rs16969681 showed increasing enhancer activity ([Figure 2](#fig2){ref-type="fig"}B). The smallest construct, with the greatest enhancer activity, showed rs16969681's high-risk allele to have almost double the activity of the low-risk allele (p = 0.029). Deletion of the rs16969681 region, leaving rs16969862 alone, showed no enhancing effect. Thus, we found that the region containing rs16969681 carries the hallmarks of an allele-specific transcriptional enhancer.

*Grem1* Levels Modify Intestinal Tumorigenesis in Mice {#sec2.3}
------------------------------------------------------

We wished to test whether modest changes in *GREM1* levels, such as those resulting from the rs16969681 genotype, could affect intestinal tumorigenesis in vivo. Because the region around rs16969681 is not highly conserved, we used constitutionally heterozygous *Grem1*^*+/−*^ mice ([@bib6]) as a model for the effects of rs16969681. We confirmed that these animals had ∼50% reduced *Grem1* mRNA expression relative to wild-type mice and showed no intestinal abnormalities or polyposis phenotype. *Grem1*^+/−^;*Apc*^*Min*/+^ animals had a \>50% reduction in adenomas compared with their well-characterized *Grem1*^*+/+*^;*Apc*^*Min/+*^ littermates (p = 0.0162; Wilcoxon test; [Figure 2](#fig2){ref-type="fig"}C; [@bib16]). We examined tumors from littermates for differences in proliferation (Ki67 immunohistochemistry), apoptosis (Casp3), Wnt signaling (β-catenin), stem cell numbers (Sox9), and canonical BMP pathway activity (phospho-Smad1,5,8). We observed increased apoptosis in *Grem1*^+/−^;*Apc*^*Min*/+^ tumors (p = 0.044; n = 12; t test) and no other differences between the mouse genotypes.

The rs16969681 Enhancer Shows Tissue-Specific Activity In Vivo {#sec2.4}
--------------------------------------------------------------

In order to confirm that the rs16969681 enhancer is functional in vivo, we generated transgenic mice carrying a 2 kb fragment containing rs16969681 upstream of a *LacZ* reporter gene. β-galactosidase expression was found specifically in the intestines and stomach and was absent from other tissues ([Figure 2](#fig2){ref-type="fig"}D). Interestingly, reporter expression was seen in both mesenchymal and epithelial cells of the intestine ([Figure 2](#fig2){ref-type="fig"}Diii), though *GREM1* is not normally expressed in the epithelium. This suggests an epithelial role for the enhancer.

CDX2 and TCF7L2 Bind the Enhancer in an Allele-Specific Fashion and CDX2 Drives *GREM1* Expression {#sec2.5}
--------------------------------------------------------------------------------------------------

Next, we sought to identify the mechanism by which rs16969681 genotype could modify enhancer activity by identifying transcription factors (TFs) that bound to the surrounding region. We used biotin-labeled electrophoretic mobility shift assay probes, a development of [@bib2] to pull down DNA-protein complexes from SW948 and C99 nuclear extracts, followed by quantitative mass-spectrometry (N.C.H., L.N.N., N.C. Hornig, and H.G.S., unpublished data). We combined these data, in silico predictions from Biobase/TRANSFAC in a 50 bp region around rs16969681, and mining of public ChIP sequencing (ChIP-seq) databases ([@bib12; @bib19]) to generate a list of candidate TFs. We assessed these proteins using ChIP in *GREM1*-expressing cells (C99 rs16969681 T/T, LS180 C/C, SW1222 C/T, and SW948 C/C) and a nonexpressing line (SW48 C/C). CDX2 and TCF7L2 (also known as TCF4) bound to the rs16969681 region ([Figure 3](#fig3){ref-type="fig"}A), as did p300, RUNX1, and, less reliably, HNF4A ([Figure S3](#app2){ref-type="sec"}). TCF7L2, HNF4A, and p300 are also listed as binding in published ENCODE data.

In order to investigate allele-specific TF binding, we quantified rs16969681 alleles in the ChIP output from the heterozygous cell line SW1222. p300 and RUNX1 showed no evidence of allele-specific binding (p \> 0.5). HNF4A binding was not present in all heterozygous cell lines. However, CDX2 (odds ratio \[OR\] = 4.7; p = 0.001; n = 81; Fisher's exact test) and TCF7L2 (OR = 2.0; p = 0.028; n = 63) showed a significant bias toward the risk allele ([Figure 3](#fig3){ref-type="fig"}B). We also found a correlation between *GREM1* and *CDX2* mRNA expression in our panel of CRC cell lines (p = 0.0088; n = 34; Spearman's rank correlation). These data again indicate that the enhancer at rs16969681 is important in cells of epithelial origin.

The core consensus CDX2-binding motif, ATAAA ([@bib19]), occurs both 14 bp upstream and 65 bp downstream of rs16969681. To confirm that the CDX2-binding region of the rs16969681 enhancer is important for its activity, we deleted a 71 bp fragment from our luciferase reporter constructs ([Figure 2](#fig2){ref-type="fig"}B), removing rs16969681 and disrupting the bases adjacent to the core CDX2-binding motifs. [Figure 3](#fig3){ref-type="fig"}C shows the resultant significant reduction in enhancer activity and loss of allele-specific expression in SW948 cells. To demonstrate that CDX2 protein can directly regulate *GREM1* transcription, we overexpressed CDX2 in SW480, a CRCCL with low endogenous CDX2 and *GREM1*. We achieved consistent CDX2 overexpression using two separate constructs, causing an ∼3.5-fold increase in *GREM1* expression (p = 0.0005; [Figure 3](#fig3){ref-type="fig"}D). By comparison, in cell lines with already high levels of GREM1 or CDX2, no effect or less consistent results were seen.

Epithelial *GREM1* Expression Occurs in Sporadic Colorectal Adenomas {#sec2.6}
--------------------------------------------------------------------

Several lines of evidence presented above suggest that the rs16969681 genotype might have its effects in dysplastic colorectal epithelium, that is, at a stage after tumor initiation ([@bib3]). We noted that CDX2 expression occurs in almost all colorectal adenomas but is lost in some CRCs ([@bib13]), and we therefore wondered whether *GREM1* is expressed in adenomas as well as CRCs. We assayed *GREM1* mRNA expression in 15 isolated crypts from three sporadic adenomas and found a 10-fold increase in epithelial expression compared with surrounding normal epithelial tissue (p = 0.002; ANOVA; [Figure 3](#fig3){ref-type="fig"}E).

Concluding Remarks and Proposed Model of *GREM1* Regulation by CDX2 and TCF7L2 Binding to the rs16969681 Enhancer {#sec2.7}
-----------------------------------------------------------------------------------------------------------------

We have found that the *GREM1* locus harbors at least two SNPs that independently influence the risk of CRC. Studies of *Grem1* expression in the developing limb bud ([@bib22]) have shown that proximal and distal global control regions (GCRs) near *GREM1* regulate gene expression in a complex fashion. The SNP rs16969681 lies upstream of *GREM1* in a region distinct from the known GCRs and is close to a regulatory element that we have shown to act as an allele-specific *GREM1* enhancer. Mouse models confirm that relatively modest changes in *Grem1* expression influence intestinal tumor burden, possibly through variation in apoptosis. The rs16969681 region differentially binds the intestine-specific TF CDX2 and the Wnt effector TCF7L2. Both these transcription factors play important roles in intestinal function and often co-occupy binding sites ([@bib19; @bib20]). CDX2 is described as a master TF that establishes intestinal epithelial identity ([@bib5; @bib13]) and maintains open chromatin ([@bib20]) for TFs such as TCF7L2. Although further investigation is required, we hypothesize ([Figure 4](#fig4){ref-type="fig"}) that, with the possible exception of the stem cell compartment, CDX2 allows TCF7L2 to act as repressor in the Wnt-low environment of the normal epithelium. However, with high levels of Wnt, such as colorectal tumors, TCF7L2 complexes with β-catenin and drives *GREM1* expression, promoting tumorigenesis.

Experimental Procedures {#sec3}
=======================

Detailed methodology is presented in [Supplemental Information](#app2){ref-type="sec"}. All error bars represent the SEM.

CRC Patients {#sec3.1}
------------

Sample sets are those reported in [@bib21], plus UK2 and Scotland2 reported in [@bib17].

Formaldehyde-Assisted Identification of Regulatory Elements {#sec3.2}
-----------------------------------------------------------

FAIRE was carried out using the method adapted from [@bib7]. Briefly, ∼10^8^ cells were crosslinked for 5 min with 1% formaldehyde, neutralized, washed, and scraped. Uncrosslinked cells were used as a control. Cells were lysed and the chromatin sonicated and extracted with phenol:chloroform. Purified DNA was analyzed by SYBR green quantitative PCR (qPCR) using primers from [Table S2](#app2){ref-type="sec"}.

Native ChIP {#sec3.3}
-----------

Native ChIP was carried out as previously described ([@bib18]). Approximately 10^8^ cells were collected, washed in PBS, and lysed, and chromatin was purified using a sucrose cushion. Chromatin was fragmented with MNase1, and immunoprecipitation (H3K4Me2, 07-030 Millipore; H4Ac, 06-866 Millipore) was carried out overnight. Antibody complexes were captured with protein A or G Dynabeads (Invitrogen) and washed. DNA was eluted and purified. Purified DNA was analyzed by SYBR green qPCR as above.

Crosslinked ChIP {#sec3.4}
----------------

Approximately 10^8^ cells were crosslinked for 10 min with 1% formaldehyde, neutralized, washed, and scraped. Cells were lysed and the chromatin sonicated prior to overnight immunoprecipitation (anti-CDX2, Bethyl Laboratories; anti-TCF7L2, Santa Cruz). Antibody complexes were incubated with protein A or G beads, washed, and eluted. Purified DNA was analyzed by SYBR green qPCR as above. For allelic analysis, PCR products were TA cloned using pGem TAeasy (Promega) followed by colony PCR and sequencing.

Sequenom MassARRAY {#sec3.5}
------------------

For ASE analysis, genomic DNA and RNA were extracted from CRCCLs COLO320 and SW403 and cDNA generated. Paired cDNA and genomic DNA samples, in triplicate, were processed using the Iplex assay and detected by Sequenom MALDI-TOF mass spectrometry. The products were run using the Sequenom genotyping protocol, visualized using the MassARRAY Typer 4.0, and the areas under the curves used to calculate the allelic ratios of each sample.

Luciferase Reporter Assays {#sec3.6}
--------------------------

Luciferase reporter assays were carried out as described ([@bib11]). Briefly, putative enhancer fragments in the pGL3 promoter vector (Promega) were cotransfected into SW948 cells with 1/10 concentration of pGL4 Renilla vector. Luciferase and Renilla activity was measured using the Dual Luciferase Assay system (Promega) and the Avent luminometer. Readings were normalized and expressed relative to a control plasmid.

Transgenic Reporter Assays {#sec3.7}
--------------------------

All work was performed according to Spanish regulations for animal experimentation and approved by the Consejo Superior de Investigaciones Cientificas ethics committee. Two-kilobase constructs containing rs16969681 and rs16969862, the minimal beta-globin promoter, *LacZ*, and a SV40 polyadenylation signal were linearized, diluted to 5 ng/ml in microinjection buffer, and used to inject fertilized mouse eggs from CBA/Ca × C57Bl/6 crosses. F0 embryos of 9.5--13 days postcoitum (dpc) stages and tissues from F0 animals at postnatal day 1 (P1) and P35 were harvested. Embryos and dissected tissues were fixed overnight, washed and placed in 10 ml of X-gal solution for 2--20 hr at 37°C, and then postfixed.

ChIP-Seq Data Mining {#sec3.8}
--------------------

CDX2 ChIP-seq data from CACO2 cells (Gene Expression Omnibus series [GSE23436](ncbi-geo:GSE23436){#intref0010}; [@bib19]) and TCF7L2 data from LS147T cells (series [GSE18481](ncbi-geo:GSE18481){#intref0015}; [@bib12]) were downloaded and mined for signals in the *GREM1* gene and surrounding region.

CDX2 Overexpression Assays {#sec3.9}
--------------------------

SW480 cells were plated out and transfected with CMVCDX2 (Addgene) and CMVFLAG-CDX2 ([@bib1]). Cells were lysed, RNA and cDNA generated, and *CDX2* and *GREM1* mRNA levels measured by quantitative RT-PCR (qRT-PCR) using the Taqman system (Applied Biosystems).

Adenoma GREM1 mRNA Expression {#sec3.10}
-----------------------------

Individual crypts from normal and adenomatous patient epithelium were isolated as described previously ([@bib11]) to ensure exclusion of any pericryptal myofibroblasts. cDNA was generated and analyzed by qRT-PCR as above.

Transgenic Mouse Crosses {#sec3.11}
------------------------

*Grem1*^*+/flox*^ mice, a kind gift of E. Canalis, were crossed with *Pgk*-*Cre* mice to inactivate one copy of *Grem1* in the germline. These mice were crossed with *Apc*^*Min*/+^ mice to generate *Grem1*^+/−^; *Apc*^*Min*/+^ and *Grem1*^+/+^; *Apc*^*Min*/+^ animals. Mice were aged for 5 to 6 months and litters sacrificed when one member showed symptoms of intestinal tumors. Intestines were dissected, fixed, and stained and polyps counted. All procedures were carried out in accordance with Home Office UK regulations and the Animals (Scientific Procedures) Act 1986. Mice were housed at the Functional Genomics Facility, Wellcome Trust Centre for Human Genetics, Oxford.

Immunohistochemistry {#sec3.12}
--------------------

Immunohistochemistry was performed as described in [@bib11] using anti-CASP3 (R&D Systems).
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![Chromatin Profiling Upstream of *GREM1*\
(A) Diagram showing position on chromosome 15 and the main features in the 25 kb region upstream of the promoter, TSS, and transcribed region of *GREM1* (chr15:32.9--33.025 Mb; hg37), including exons (green boxes) and SNPs (black marks). Regional interspecific conservation (University of California, Santa Cruz phyloP100way all \[vert.\]), DNase1 hypersensitivity (wgEncodeReg Dnase Clustered V2), and TF-binding (wgEncodeReg Tfbs Clustered V3) sites are also shown in the bottom panel. TFs that bind at or adjacent to rs16969681 in ENCODE nonintestinal cell lines include HDAC2, BHLHE40, FOXA1, FOXA2, MAFK, HNF4G, SP1, RXRA, GATA3, MYBL2, p300, HNF4A, and TCF7L2.\
(B) FAIRE assay on four CRCCLs: LS180 (*GREM1*-high; rs16969681 C/C), C99 (*GREM1*-high; T/T), HCC56 (*GREM1*-low; T/T), and SW48 (*GREM1* null; C/C). The graph shows relative enrichment at each primer set as determined by the ΔΔCt method, first by using noncrosslinked genomic DNA to normalize the results from nucleosome-depleted DNA and then by expressing each primer set relative to primers at chr15:32,993,925, telomeric to the rs16969681 signal.\
(C and D) ChIP assays with anti-H3K4Me2 and anti-H4Ac antibodies, respectively, analyzed by SYBR green qPCR on four CRC cell lines as in (B). Relative enrichment was determined by the ΔΔCt method using sonicated input DNA to normalize the values from immunoprecipitated DNA and expressing this ratio relative to that seen at the *Rhodopsin* promoter as a negative control.\
(B), (C), and (D) all show an area of active chromatin in the region surrounding rs16969681 with rs16969862 at its telomeric edge. Chromatin at rs4779584 shows no enrichment for activating marks. See also [Table S1](#app2){ref-type="sec"} and [Figures S1](#app2){ref-type="sec"} and [S2](#app2){ref-type="sec"}.](gr1){#fig1}

![Allele-Specific Effects of an Enhancer at rs16969681\
(A) rs16969681 heterozygote COLO320 shows allele-specific expression of *GREM1*. cDNA isolated from COLO320 cells was analyzed to measure ASE of SNP rs7162202 (*GREM1* 3′ UTR). The chart shows the results after normalization with COLO320 genomic DNA. There was a mean G/T ratio of 1.62 (p = 0.001; t test). rs16969681 homozygous cell line SW403 showed a normalized ratio of 1.13 (p = 0.11).\
(B) Luciferase reporter assays to analyze the enhancer activity of 1.0--4.1 kb fragments containing rs16969681 upstream of *GREM1* using the pGL3 promoter vector in SW948 cells. Scale diagrams are drawn for each fragment. Green arrows represent the low-risk and red arrows the high-risk allele. The bar chart shows the average luciferase activity of triplicate experiments normalized using the pGL4 Renilla activity and expressed relative to pGL3 containing a neutral stretch of DNA (control). The high-risk allele causes a significant increase in enhancer activity (p \< 0.0002). The smallest (1.4 kb) fragment containing rs16969681 shows high activity, which is increased nearly 2-fold in the presence of the risk allele (p = 0.029).\
(C) Box plot showing significant reduction in polyp numbers in *Grem1*^+/−^;*Apc*^*Min*/+^ mice compared to *Grem1*^+/+^;*Apc*^*Min*/+^ littermates. In the former, mean polyp number at 5 to 6 months was 18 (n = 5; SD = 4.4); in the latter, mean polyp number was 43 (n = 9; SD = 22; p = 0.0162; Wilcoxon test).\
(D) Gastrointestinal expression of a rs16969681-*LacZ* reporter construct. Intestines and stomachs were removed from transient transgenic mice (16 dpc). The upper panels show β-galactosidase expression in the reporter animal (i), but not in wild-type controls (ii). The lower panels show anti-β-galactosidase immunofluorescence (red). Reporter expression is present in both the mesenchymal (lower) and epithelial compartments (upper) of the intestine in transgenic mice (iii), but not their wild-type littermates (iv).\
Error bars represent SEM.](gr2){#fig2}

![CDX2 Binding at rs16969681 in *GREM1*-Expressing CRCCLs and Its Effect on *GREM1* Expression\
(A) ChIP assays with anti-CDX2 and anti-TCF7L2 antibodies analyzed by SYBR green qPCR on a number of CRC cell lines (C99 T/T, LS180 C/C, SW1222 C/T, SW48 C/C, and SW948 C/C). The graphs show enrichment around rs16969681 in *GREM1*-expressing cell lines irrespective of genotype. Relative enrichment was determined by the ΔΔCt method, using sonicated input DNA to normalize the enrichment seen in immunoprecipitated DNA and then expressing each primer set relative to primers at chr15: 32,993,925. Despite repeated attempts, COLO320 (C/T) chromatin did not immunoprecipitate efficiently enough for use in ChIP assays.\
(B) Sanger sequence traces of input, CDX2 ChIP, and TCF7L2 ChIP output from SW1222 highlighting rs16969681. A bias toward the risk T allele (red) at rs16969681 in the ChIP output is not seen in the input. This was confirmed by formal allele counting.\
(C) Luciferase reporter assays to analyze the enhancer activity of *GREM1* upstream fragments containing the 1.4 kb around rs16969681 cloned into pGL3 promoter vector carried out in SW948 cells. Green arrows represent the low-risk alleles and red arrows the high risk. Black squares denote CDX2 core-binding motifs. The graph shows the average luciferase activity of three experiments (where each construct was analyzed in triplicate) normalized using the pGL4 Renilla activity and expressed relative to pGL3 promoter containing a neutral stretch of DNA (control). Deletion of a 71 bp EcoR1/ZraI fragment removing rs16969681 and disrupting bases adjacent to CDX2-binding motifs caused a significant reduction in enhancer activity.\
(D) CDX2 overexpression experiment to analyze the effect on endogenous *GREM1* mRNA expression. Two CMV-CDX2 expression plasmids and an empty vector were each transfected in triplicate into the SW480 CRCCL, chosen for its low endogenous *CDX2* and *GREM1* expression and its consistently high levels of *CDX2* following transfection (confirmed by both qRT-PCR and western blot). mRNA was extracted and analyzed by Taqman, also in triplicate. The chart shows the relative expression of *GREM1* mRNA in the overexpression samples compared to empty vector calculated using the ΔΔCt method, normalized to *GAPDH*. Each overexpression plasmid individually caused a similar ∼3.5-fold increase in *GREM1* expression. The chart shows the combined results from both (p = 0.0005; t test).\
(E) *GREM1* expression in three sporadic adenomas relative to paired normal tissue. Two to six crypts were isolated from each sample and mRNA levels analyzed by Taqman qRT-PCR. The chart shows relative *GREM1* levels calculated by ΔΔCt, normalized to *GAPDH*. Adenomas had a mean of 10.3 times more *GREM1* mRNA than paired normal crypts (p = 0.006; t test).\
See also [Figure S3](#app2){ref-type="sec"}. Error bars represent SEM.](gr3){#fig3}

![Proposed Model of Action of CDX2 and TCF7L2 on *GREM1* Expression through Binding Close to rs16969681\
The model describes how the rs16969681 enhancer might regulate *GREM1* transcription in (A) normal intestines and (B) adenomas based on the previously proposed model of CDX2 acting as a pioneer TF for TCF7L2.\
(A) The normal crypt is subjected to a Wnt gradient with high levels at the base and low/absent levels at the neck. The top panel (blue) shows the situation for most normal crypt epithelium cells. Here, CDX2 binds to the enhancer, partially disrupting the repressive chromatin, but Wnt signaling, and therefore active β-catenin, is at low or moderate levels, so the majority of TCF7L2 is bound by repressors such as Groucho ([@bib4; @bib14]). Allele-specific effects of CDX2 binding are not apparent because *GREM1* expression is at a very low basal level and essentially repressed. There is no enhancer activity. In the middle panel, Wnt levels are higher, as for example in the stem cell zone at the crypt base. Here, activated TCF7L2/β-catenin complexes bind together with CDX2 and low levels of enhancer activity result; this is consistent with evidence that intestinal stem cells produce low levels of secreted BMP antagonists ([@bib9]). The bottom panel (orange) shows the mesenchyme, where no CDX2 is present, although there are high levels of Wnt. *GREM1* expression is activated by unknown mesenchymal enhancers or mesenchyme-specific TFs binding at rs16969681.\
(B) In the pathological setting of an adenoma, *APC* or *CTNNB1* mutations cause constitutive Wnt activation and high levels of Wnt target gene expression. CDX2 opens up the chromatin, allowing high levels of activated TCF7L2/β-catenin to cause *GREM1* transcription. On the rs16969681 risk allele (bottom panel), extra CDX2 binding results in higher enhancer activity. The downstream effects of the increased *GREM1* may include an increase in stem-like cells and angiogenesis.](gr4){#fig4}
